Products for Research Use Only
RegisterLogin

Altiratinib

CAT: 0804-HY-B0791-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0791-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
CAS Number
1345847-93-9
Product Name Alternative
DCC-2701
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
C-Met/HGFR; FLT3; Trk Receptor; VEGFR
Type
Reference compound
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Altiratinib.html
Purity
99.29
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F
Molecular Formula
C26H21F3N4O4
Molecular Weight
510.46
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Smith BD, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated DrugResistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep;14 (9) :2023-34.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
TrkA; TrkB; TrkC; VEGFR2/KDR/Flk-1

Alternative Products

CatalogName
474056Altiratinib
MBS3840338-01Altiratinib (DCC2701)
MBS575617Altiratinib(DCC2701)
A14387-5Altiratinib 5mg
A14387-25Altiratinib 25mg
A14387-10Altiratinib 10mg
MBS130772-01Altiratinib(DCC-2701)
A14387-100Altiratinib (DCC2701) 100mg

Popular Products